Developing a bioprinted scaffold‐based model of neurodegeneration for high throughput screening in Drug Development

A major component of the failure to bring novel drugs for Alzheimer’s disease (AD) to market is the translational gap between in vitro, animal and human studies. Using the novel technology of 3D bio‐printing, this project aims to develop a scaffold‐based 3D quad‐culture model of AD for drug screening using human induced pluripotent stem cells.